Company Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits.
The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies.
It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America.
It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases.
The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005.
Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 27, 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 796 |
| CEO | Christian O. Henry |
Contact Details
Address: 1305 O’Brien Drive Menlo Park, California 94025 United States | |
| Phone | 650 521 8000 |
| Website | pacb.com |
Stock Details
| Ticker Symbol | PACB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001299130 |
| CUSIP Number | 69404D108 |
| ISIN Number | US69404D1081 |
| Employer ID | 16-1590339 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Christian O. Henry M.B.A. | President, Chief Executive Officer, Interim Chief Financial Officer and Director |
| Mark Van Oene Ph.D. | Chief Operating Officer |
| Dr. Stephen Turner Ph.D. | Co-Founder |
| Michele Farmer CPA | Vice President and Chief Accounting Officer |
| Dr. Brett Atkins J.D., Ph.D. | General Counsel and Corporate Secretary |
| Natalie Welch | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 8-K/A | [Amend] Current report |
| Dec 10, 2024 | SCHEDULE 13G | Filing |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |